 | Not displayed, CONTACT the Zenopa Account Manager Jo-Anne on 01494 818 012 or jo@zenopa.com for CURRENT and future vacancies.
|  |
|  | Takeda Jobs Profile | Company Overview
Takeda UK was established in 1997 to coincide with the launch of candesartan cilexetil (Amias®), an angiotensin receptor blocker (ARB). Candesartan cilexetil was co-promoted with business partner AstraZeneca. Takeda UK now holds the sole marketing rights to candesartan cilexetil in the UK and candesartan is now the UK's second most prescribed ARB.
In November 2000 Takeda UK launched another new compound, pioglitazone (Actos®), a member of the thiazolidinedione (TZD) class for treating type 2 diabetes. Pioglitazone has achieved a monthly turnover of over 30,000 treatment units and, as a key treatment option in diabetes and endocrinology, it is enjoying rapid and increased uptake. The success of the pioglitazone launch resulted in Takeda UK jointly winning the prestigious Pharmaceutical Company of the Year section at the 2001 Pharmaceutical Marketing Effectiveness Awards.
Takeda UK's challenge in 1997 was to firmly establish the company in the UK market. Based on the success of candesartan cilexetil and pioglitazone, Takeda UK IMS turnover for the calendar year of 2004 was £50.7 million. This level of sales, coupled with continued growth, has seen Takeda UK gain a top 30 ranking among UK pharmaceutical companies.
Takeda UK remains the fastest growing pharmaceutical company in the UK top 50. The company is firmly established and is ideally positioned for the next phase in its growth cycle.
Product Overview
At Takeda UK we focus on three key therapeutic areas:
- Diabetes
Takeda originated the class of thiazolidinediones (TZDs) which target insulin resistance, a fundamental trigger of type 2 diabetes, and market a product in this class, pioglitazone (Actos®).
- Hypertension
Takeda pioneered the class of angiotensin receptor blockers (ARBs) and market a product in this class, candesartan cilexetil (Amias®) which is licensed for the treatment of hypertension and heart failure with left ventricular systolic dysfunction (LVSD).
- Heart Failure
Takeda pioneered the class of angiotensin receptor blockers (ARBs) and market a product in this class, candesartan cilexetil (Amias®) which is licensed for the treatment of heart failure with left ventricular systolic dysfunction (LVSD) and hypertension.
|  |
|
|  | Jo-Anne
Takeda Account Manager
01494 818 012
(Mon to Fri 0830 to 1800 hours)
jo@zenopa.com
| |
|
